Sun Pharma is officially buying Organon for $14.00 per share in cash, valuing the company at $11.75 billion. The deal would make the combined entity a top 3 player in global women's health and the 7th largest biosimilar company worldwide, with a presence in 150 countries and combined revenues of $12.4 billion. For Organon stockholders, it's a clean cash exit. The transaction is expected to close in early 2027, pending regulatory and stockholder approvals.
"This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform"
— Dilip Shanghvi, Executive Chairman, Sun Pharma
🔗 https://sunpharma.com/wp-content/uploads/2026/04/PR-Sun-Organon-announcement-Apr-26.pdf
PreludeDx has secured FDA Breakthrough Device designation for AidaBREAST, a multi-omic diagnostic test for women with early-stage invasive breast cancer. It's the only test of its kind that predicts both 10-year recurrence risk and whether a patient is likely to benefit from radiation therapy after breast-conserving surgery - helping doctors and patients make more personalised treatment decisions. PreludeDx now holds Breakthrough Device designations for two products.
"AidaBREAST addresses an important need in early-stage invasive breast cancer by providing both recurrence risk assessment and insight into which patients are most likely to benefit from radiation therapy. With Breakthrough Device designations for both DCISionRT and AidaBREAST, we are continuing to advance precision diagnostics that support more informed treatment decisions for patients and physicians."
— Dan Forche, President & CEO, PreludeDx
Tandem's Control-IQ+ technology has received FDA clearance for use during pregnancy in women with Type 1 diabetes - a first for automated insulin delivery. Managing blood sugar during pregnancy is notoriously difficult and high-stakes, and until now no closed-loop system had been cleared for this population. It's a meaningful step forward for maternal health and diabetes care.
The Toronto-based startup behind VIOLET, MAGENTA and ROSE - AI tools that assess egg quality during IVF and egg freezing - has raised $4.1M led by M Ventures and Whitecap Venture Partners. Its models have been trained on over 650,000 oocyte images and are already live in 300+ clinics across 35 countries. The funding will support expansion into Asia-Pacific and the US, including an FDA 510(k) clearance push.
Swiss biotech Debiopharm has received FDA Fast Track designation for the combination of lunresertib and zedoresertib in platinum-resistant ovarian cancer with specific genomic markers. The designation follows the first clinical data from the MYTHIC trial, presented at AACR 2026. For patients who've run out of platinum-based options, this combination targets a very specific genomic vulnerability - and Fast Track status means a faster path to potential approval.
"The FDA's decision to grant Fast Track designation for this combination therapy validates our synthetic lethality approach to treating high-unmet-need cancers. This designation highlights the potential of combining lunresertib and zedoresertib to provide a meaningful new clinical option for patients with biomarker-selected ovarian cancer who have exhausted platinum-based therapies."
— Esteban Rodrigo Imedio, Executive Medical Director, Oncology, Debiopharm
The World Health Organisation has released ChatHRP for beta-testing - an AI tool built exclusively on verified WHO and HRP research, designed to give policymakers, healthcare workers and researchers fast access to reliable sexual and reproductive health information. It has multilingual capabilities and works on low bandwidth, making it genuinely global in scope. It's a direct response to the growing problem of reproductive health misinformation online.
Founded in 1996 by two people brought together by a personal experience with breast cancer, the Breast Cancer Research Foundation of Alabama has now invested $17 million in statewide research over three decades. It's a milestone worth noting - grassroots, mission-driven funding that has quietly built one of the state's most consistent engines for breast cancer science.
